이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Epigenomics 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Noel Doheny

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	13.2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

CEO

Noel Doheny

13.2yrs

테뉴어

Dr. Noel Thomas Doheny has been the Chief Executive Officer of Epigenomics Inc. at Epigenomics AG since May 2011. Dr. Doheny manages all US activities and global business development and partnership develo...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Helge Lubenow	Chairman of the Supervisory Board	8.2yrs	€25.00k	데이터 없음
Alexander Link	Vice-chairman of Supervisory Board	4.1yrs	€25.00k	데이터 없음
Jochen Hummel	Member of Supervisory Board	less than a year	데이터 없음	데이터 없음

4.1yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: ECX 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

Epigenomics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Epigenomics AG, Annual General Meeting, May 29, 2024

Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023

Epigenomics AG Announces Resignation of Jorge Garces as Executive Board Member Effective January 31, 2021

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Price target increased by 227% to €52.65

Consensus revenue estimates fall by 11%

Consensus revenue estimates decrease by 11%

Epigenomics AG, Annual General Meeting, May 29, 2024

New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.

Consensus revenue estimates increase by 139%

Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)

Now 30% undervalued

New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.

Now 23% undervalued

A Look At The Intrinsic Value Of Epigenomics AG (ETR:ECX1)

Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5m

Price target increased by 9.1% to €6.00

First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)

Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023

Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)

Price target increased to €1.17

Consensus forecasts updated

No longer forecast to breakeven

Third quarter 2022 earnings released

Epigenomics AG to Report Q3, 2023 Results on Nov 09, 2023

Epigenomics Ag Reaffirms Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released

Price target decreased to €0.98

Epigenomics AG Confirms Outlook for Fiscal Year 2022

Price target increased to €1.07

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epigenomics AG Confirms Earnings Guidance for the Year 2022

Price target decreased to €0.95

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased to €0.95

Third quarter 2021 earnings released: EPS €0.23 (vs €0.47 loss in 3Q 2020)

Price target decreased to €1.14

New Horizon Health Limited (SEHK:6606) entered into an agreement to acquire certain non-essential biological samples from Epigenomics AG (XTRA:ECX) for $6.7 million.

Second quarter 2021 earnings released: €0.21 loss per share (vs €0.57 loss in 2Q 2020)

Price target decreased to €1.44

We're Keeping An Eye On Epigenomics' (ETR:ECX) Cash Burn Rate

Consensus forecasts updated

Forecast to breakeven in 2023

First quarter 2021 earnings released: €0.20 loss per share (vs €0.55 loss in 1Q 2020)

Epigenomics AG Announces Earnings Guidance for the Year 2021

Consensus forecasts updated

Consensus forecasts updated

Epigenomics AG Provides Earnings Guidance for the Year 2021

New 90-day low: €2.30

When Will Epigenomics AG (ETR:ECX) Breakeven?

Price target lowered to €16.27

Epigenomics AG Announces Resignation of Jorge Garces as Executive Board Member Effective January 31, 2021

Epigenomics Ag Announces the U.S. Centers for Medicare & Medicaid Services (CMS) Have Issued A Negative Reimbursement Decision in Connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' Blood Test for Colorectal Cancer Screening

Epigenomics AG to Report Fiscal Year 2020 Results on Mar 25, 2021

Epigenomics AG Pulls Revenue Guidance for the Year 2020 Due to Covid-19

Epigenomics AG announces the U.S. Centers for Medicare & Medicaid Services have issued a negative reimbursement proposal in connection with the National Coverage Determination of Epi proColon, Epigenomics' blood test for colorectal cancer screening

Epigenomics Ag Pulls Its Revenue Guidance for 2020

Earnings released

New 90-day high - €2.17

CEO

테뉴어

이사회 구성원

평균 재임 기간

평균 연령